Impact and Cost Effectiveness of Pneumococcal Conjugate Vaccine in India
This article, published in Vaccine, reports the results of a modeling study to estimate the impact and cost-effectiveness of pneumococcal conjugate vaccine (PCV) in India, which is being introduced in a phased manner into the Universal Immunization Programme. The results indicate that the PCV program is a highly cost-effective intervention in India and justifies the introduction of PCV into the routine immunization schedule in some of the states. The authors recommend introducing the vaccine throughout the country to reduce morbidity and mortality among children under five years of age. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)
Author: Krishnamoorthy Y, Eliyas SK, Nair NP, Sakthivel M, Sarveswaran G, Chinnakali P
» Visit web page (English)
(Located at www.sciencedirect.com)
Citation: Krishnamoorthy Y, Eliyas SK, Nair NP, Sakthivel M, Sarveswaran G, Chinnakali P. Impact and Cost Effectiveness of Pneumococcal Conjugate Vaccine in India. Vaccine. 2019;37(4):623-630.
Resource types: Peer-reviewed journal